Published: 2017-10-27

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase IV Study)

Bruce Strober, Jerry Bagel, Mark Lebwohl, Linda Stein Gold, J Mark Jackson, Joana Goncalves, Eugenia Levi, Kristina Callis Duffin

Page s11

Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

Andrew Blauvelt, Craig Leonardi, Claus Zachariae, Russel Burge, Terri Ridenour, Missy McKean-Matthews, Sandra Garces, Gregory Cameron

Page s12

Efficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study)

Jerry Bagel, Mark Lebwohl, Linda Stein Gold, J Mark Jackson, Joana Goncalves, Eugenia Levi, Kristin Callis Duffin, Bruce Strober

Page s13

Evaluation of the PGAxBSA Composite Tool in Patients with Moderate-to-Severe Plaque Psoriasis

Kristina Callis Duffin, J Mark Jackson, Joana Goncalves, Eugenia Levi, Jerry Bagel

Page s14

First "Real-World" Insights on Apremilast Treatment for Patients with Plaque Psoriasis from the LAPIS-PSO Study: An Interim Analysis

Kristian Reich, Stefanie Bomas, Bernhard Korge, Maria Manasterski, Uwe Schwitchtenberg, Hannah Mentz, Kathrin Groegel

Page s15

Improvements in Lesional Pain and Itch Symptoms with Brodalumab in Psoriasis Studies

Lawrence F Eichenfield, April Armstrong, Lawrence Green, Shipra Rastogi, Radhakrishnan Pillai, Robert Israel

Page s17

Incidence of Inflammatory Bowel Disease Events in Adalimumab Clinical Trials Across Indications

Jeffrey R Curtis, Dirk Elewaut, Su Chen, Maja Hojnik, Navit Naveh, Jaclyn K Anderson

Page s18

Innovation in Topical Therapy for Psoriasis with Corticostereoid and Vitamin D Analogue Commbination

Siegfried Segaert, Neal Shear, Andrea Chiricozzi, Diamant Thaci, Jose M Carrascosa, Helen Young, Vincent Descamps

Page s19

Lack of Placental Transfer of Certolizumab Pegol During Pregnancy: Results from CRIB, a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study

Alexa B Kimball, Xavier Mariette, Bincy Abraham, Ann Flynn, Frauke Forger, Anna Molto, Rene Marc Flipo, Astrid van Tubergen, Laura Shaughnessy, Jeff Simpson, Marie Teil, Eric Helmer, Maggie Wang, Eliza Chakravarty

Page s21

Neuropsychiatric Adverse Events in Brodalumab Psoriasis Studies

Mark Lebwohl, Kim A Papp, Jashin J Wu, Andrew Blauvelt, Alan Menter, Shipra Rastogi, Radhakrishnan Pillai, Robert Israel

Page s25

Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks

Desiree van der Heijde, Masato Okada, Chin Lee, Catherine L Shuler, Suchitrita Rathmann, Chen-Yen Lin, Philip J Mease

Page s28

Atopic Dermatitis

Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis

Eric Simpson, Andrew Bushmakin, Joseph C Cappelleri, Thomas Luger, Sonja Stander, Wynnis Tom, William C Ports, Anna M Tallman, Huaming Tan, Robert A Gerber

Page s36

Dupilumab with Concomitant Topical Corticosteroids in Atopic Dermatitis Patients who are Inadequately Controlled with or Medically Inadvisable for Cyclosporine A: a Phase 3 Clinical Trial (LIBERTY AD CAFE)

Marjolein de Bruin-Weller, Diamant Thaci, Catherine Smith, Allen Radin, Rick Zhang, Bolanle Akinlade, Abhijit Gadkari, Laurent Eckert, Thomas Hultsch, Gianluca Pirozzi, Neil MH Graham, Brad Shumel

Page s37

Dupilumab in Moderate-to-Severe Atopic Dermatitis: Pooled Efficacy Results from Two Identically Designed Randomized Phase 3 Trials (SOLO 1 & 2)

Carlos Ferrandiz, Pablo de la Cueva Dobao, Eric L Simpson, Rick Zhang, Abjijit Gadkari, Laurent Eckert, Bolanle Akinlade, Marius Ardeleanu

Page s38

The Effect of Crisaborole Ointment, 2%, on Pruritus in Patients with Atopic Dermatitis: An Extended Analysis

Gil Yosipovitch, Eric Simpson, Huaming Tan, Robert A Gerber, Thomas Luger, Sonja Stander, Wynnis Tom, Joseph C Cappelleri, Andrew G Bushmakin, William C Ports, Anna M Tallman

Page s39

Validation of the Severity of Pruritus Scale for the Assessment of Pruritus in Atopic Dermatitis

Gil Yosipovitch, Eric Simpson, Andrew G Bushmakin, Joseph C Cappelleri, Thomas Luger, Sonja Stander, Wynnis Tom, Katy Benjamin, William C Ports, Anna M Tallman

Page s45

Acne & Rosacea

Efficacy and Saftey of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Subjects with Severe Inflammatory Acne (Non-Nodulocystic) that are Candidates for Oral Isotretinoin

James Del Rosso, Linda Stein Gold, Sandra Marchese Johnson, Maria Jose Rueda, Hilary Baldwin, Edward L Lain, Megan Landis, Marta Rendon, Emil Tanghetti, Jonathan Weiss

Page s48

Rapid Improvement with BPX-01 Minocycline Topical Gel in the Treatment of Moderate-to-Severe Inflammatory Acne Vulgaris: a Randomized, Double-Blind, Vehicle-Controlled Study

Andrew Alexis, James Del Rosso, Seemal R Desai, Jeanine Downie, Zoe D Draelos, Christina Feser, Rion Forconi, Joseph Fowler, Michael Gold, Joely Kaufman-Janette, Edward Lain, Mark Lee, Mark Ling, Ava Shamban, William Werschler, AnnaMarie Daniels

Page s53

Disorders of Pigmentation

Hidradenitis Suppurativa

Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)

Christos C Zouboulis, Martin M Okun, Robert Gniadecki, Peter A Foley, Charles Lynde, Jamie Weisman, Piyalal Karunaratne, David A Williams

Page s128


Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Axillary Hyperhidrosis

Dee Anna Glaser, Adelaide A Hebert, Alexander Nast, William P Werschler, Stephen Shideler, Lawrence Green, Richard D Mamelok, Janice Drew, John Quiring, David M Pariser

Page s95




Efficacy and Safety of OnabotulinumtoxinA for Treatment of Moderate-to-Severe Forehead Lines

Steve Fagien, Joel Cohen, William Coleman, Gary Monheit, Jean Caruthers, Cheri Mao, Domenico Vitarella, Xiaofang Lei, Bhushan Hardas

Page s72

Efficacy and Safety of OnabotulinumtoxinA for Moderate-to-Severe Forehead Lines in Subjects with Upper Facial Lines

Koen De Boulle, Philip Werschler, Michael H Gold, Gerhard Sattler, Patricia Ogilvie, Cheri Mao, Domenico Vitarella, Xiaofang Lei, Bhushan Hardas

Page s73

Lip and Perioral Enhancement with HA Dermal Fillers in Individuals with Fitzpatrick Skin Types IV-VI

Susan C Taylor, Jeanine B Downie, Ava Shamban, Julius Few, Bashir Khan, Andrew Schumacher, Conor Gallagher

Page s79

Maximizing Pan-Facial Aesthetic Outcomes; Findings and Recommendations from the HARMONY Study

Michael Kaminer, Joel L Cohen, Vic Narurkar, Ava Shamban, Phil Werschler, Garrett T Shumate, Conor J Gallagher

Page s80

An Observational Study of the Safety and Efficacy of Tissue Stabilized-Guided Subcision to Improve the Appearance of Cellulite

Roy G Geronemus, Jeremy A Brauer, Suzanne L Kilmer, Simeon H Wall, Jr., Jeremy B Green, Joel L Cohen, Robert A Weiss, Tina S Alster, Michael S Kaminer

Page s81

Pan-facial Treatment Positively and Significantly Impacts Social Perception

Steven Dayan, Alexander Rivkin, Jonathan M Sykes, Craig F Teller, Susan H Weinkle, Garrett T Shumate, Conor J Gallagher

Page s84

Performance of a Facial Night Moisturizer for Redness-Prone Skin

Matthew H Meckfessel, Sandrine Teissedre, Nadege Lachmann, Francince Santoro

Page s85

VYC-17.5L is Effective for the Treatment of Static and Dynamic Radial Cheek Lines: Results from the BEAM Study

Patricia Ogilvie, Bernhard Fink, Christopher Leys, Sylvia Lipko-Godlewska, Francois Niforos, Graeme Kerson, Michael Silberberg

Page s92

Nail Unit Disorders

Adalimumab for Nail Psoriasis: Efficacy and Safety from the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

Alice B Gottlieb, Boni E Elewski, Martin M Okun, Jerry Bagel, Yves Poulin, Yihua Gu, Ziqian Geng, David A Williams, Wendell C Valdecantos

Page s97

Improvement of Nail Psoriasis with Brodalumab in Phase 3 Trials

Mark G Lebwohl, Lawrence Green, Sylvia Hsu, Shipra Rastogi, Tina Lin, Radhakrishnan Pillai, Robert J Israel

Page s99


Non-Melanoma Skin Cancers and Benign Cutaneous Tumors

Daylight Photodynamic Therapy of Actinic Keratosis with BF-200 ALA compared to MAL

T Dirschka, S Ekanayake-Bohlig, R Dominicus, R Aschoff, E Herrera-Ceballos, R Botella-Estrada, A Hunfeld, B Schmitz, H Lubbert, S Puig

Page s115

Dermatologic Surgery and Wound Healing


Design and rational of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)

Gordon Sussman, Jacques Hebert, Wayne Gulliver, Charles Lynde, William H Yang, Olivier Chambenoit, Gretty Deutsch, Frederica DeTakacsy, Lenka Rihakova

Page s125

Omalizumab Retreatment of Patients swith Chronic Idopathic Urticaria/Spontaneous Urticaria (CIU/CSU) Following Return of Symptoms: Primary Results of the OPTIMA Study

Gordon Sussman, Jacques Hebert, Wayne Gulliver, Charles Lynde, William H Yang, Olivier Chambenoit, Antonio Vieira, Frederica De Takacsy, Lenka Rihakova

Page s127


Abametapir Lotion, 0.74% Demonstrates High Elimination Rates of Head Lice with a Single Application in Phase 3 Trials

Lydie Hazan, Robert S Haber, Robert S Haber, Michael Husseman, Michael Husseman, Katie Shepherd, Katie Shepherd, Sharon Hanegraaf, Sharon Hanegraaf, Tina Ahveninen, Tina Ahveninen, Lisa Jenkins, Lisa Jenkins, Hugh Alsop, Hugh Alsop, Vernon M Bowles, Vernon M Bowles

Page s131